KFAS
SUPN icon

Keating Financial Advisory Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Keating Financial Advisory Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.77K Buy
73
+61
+508% +$3.11K ﹤0.01% 1585
2025
Q4 		$596 Buy
+12
New +$583 ﹤0.01% 1918

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Keating Financial Advisory Services's SUPN Position: Q1 2026 in Review

Keating Financial Advisory Services increased its Supernus Pharmaceuticals (SUPN) stake by 508% in Q1 2026, buying an estimated $3.11K and bringing the position to 73 shares worth $3.77K. The position accounts for ﹤0.01% of the portfolio, ranked #1585.

Keating Financial Advisory Services first reported a position in SUPN in Q4 2025 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Keating Financial Advisory Services held 73 shares of Supernus Pharmaceuticals worth $3.77K as of Q1 2026.
  • Keating Financial Advisory Services bought 61 Supernus Pharmaceuticals shares in Q1 2026, an estimated $3.11K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #1585 holding.
  • Keating Financial Advisory Services first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.